arrow
Y

Yu Shyr

Vanderbilt University
H指数:116
被引数:5.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ivabradine for prevention of myocardial injury after noncardiac surgery (PREVENT-MINS trial): study protocol for a randomized controlled trial
2025-11-212
OAAI
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers

三阴性乳腺癌患者接受新辅助化疗/免疫疗法治疗的不良事件:来自七家学术医疗中心的结果

2025-07-040
OAAI
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶1 (IDH1) 和IDH2-mutant胆管癌: 来自美国国家癌症研究所10129期2试验的安全性和抗肿瘤活性

CANCER
IF5.1
2025-02-070
PRE
Identification and multimodal characterization of a specialized epithelial cell type associated with Crohn's disease
2024-08-222
OAAI
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

临床干预对肺癌患者SARS-CoV-2免疫的时间依赖性影响

2024-06-261
OAAI
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
2024-02-013
OA
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
2023-12-224
OA
NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors
2023-12-012
PRE
The Genetic Landscape of Familial Pulmonary Fibrosis

家族性肺纤维化的遗传景观

2023-05-1514
PRE
Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
2023-04-145
PRE
SeroNet Pooling Project of immunocompromised populations
2023-04-040
PRE
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

癌症患者接受两剂和三剂新型冠状病毒肺炎mRNA疫苗后的突破性SARS-CoV-2感染: 来自新型冠状病毒肺炎和癌症协会的回顾性观察研究

2023-03-0124
OAAI